Literature DB >> 2314797

Enhancing patient compliance with hormone replacement therapy at menopause.

L E Nachtigall1.   

Abstract

Physicians who prescribe hormone replacement therapy for menopausal women should explain the purpose, risks, and side effects of the treatment. This enhances compliance and discourages patients from discontinuing therapy because of fears of cancer or misconceptions about hormone replacement therapy. The physician should explain that the risk of endometrial cancer is virtually eliminated (reduced to that of a normal woman or a woman not receiving therapy) by the addition of progestogen to estrogen regimens, and that when this cancer does occur, it is usually diagnosed and treated early. Recent studies have not conclusively shown a significant effect of progestogen on lipid profiles relevant to cardiovascular disease. Hormone replacement therapy does not appear to be associated with an increased risk of breast cancer. Nuisance side effects (such as edema and breast tenderness) can be better tolerated if the physician prepares the patient, offers a solution, and helps to put the problem in perspective. Other measures, such as providing written information and avoiding unnecessary biopsies, also enhance compliance.

Entities:  

Mesh:

Year:  1990        PMID: 2314797     DOI: 10.1016/0020-7292(90)90537-u

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

Review 1.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

Review 2.  Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency.

Authors:  R Whittington; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

3.  Acute hazards to young children from residential pesticide exposures.

Authors:  M F Spann; J M Blondell; K L Hunting
Journal:  Am J Public Health       Date:  2000-06       Impact factor: 9.308

4.  Menopausal hormones and breast cancer in a biracial population.

Authors:  P G Moorman; H Kuwabara; R C Millikan; B Newman
Journal:  Am J Public Health       Date:  2000-06       Impact factor: 9.308

5.  Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995.

Authors:  M T Connelly; M Richardson; R Platt
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

Review 6.  Educating patients about the benefits and drawbacks of hormone replacement therapy.

Authors:  S Rozenberg; J B Vasquez; J Vandromme; M Kroll
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

7.  Evaluation of the effects of a new intravaginal gel, containing purified bovine colostrum, on vaginal blood flow and vaginal atrophy in ovariectomized rat.

Authors:  Silvia Vailati; Elsa Melloni; Ermanno Riscassi; Delphine Behr Roussel; Marco Sardina
Journal:  Sex Med       Date:  2013-12       Impact factor: 2.491

8.  Impact of multidisciplinary collaborative pharmaceutical care on knowledge, adherence, and efficacy of hormone therapy in climacteric women.

Authors:  Min Lu; Ying Zhou; BaoJing Wang; ZheWen Hu; Ying Du; ShiFang Liu; XiuFeng Lin; YiMin Cui; HongYan Jin
Journal:  Patient Prefer Adherence       Date:  2018-07-19       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.